论文信息 - Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP). - 字舞流文

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

M. Konopleva | H. Kantarjian | J. Cortes | K. Patel | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | N. Pemmaraju | N. Jain | N. Short | Y. Alvarado | A. Maiti | K. Naqvi | M. Yilmaz | R. Garris | Debra Bull Linderman